Copiktra (duvelisib) — Medica

Initial criteria

• age ≥ 18 years
• EITHER: (a) patient has relapsed or refractory disease AND has breast implant-associated anaplastic large cell lymphoma or hepatosplenic T-cell lymphoma OR (b) patient has peripheral T-cell lymphoma

Approval duration

1 year